Clinical TopicsWeb Exclusives
new drug acute lymphoblastic leukemia

FDA approves new drug for certain types of ALL

Share

On March 29, the U.S. Food and Drug Administration (FDA) approved Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease.

Read more via FDA.gov.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

Which of the following patients is at the highest risk for developing autonomic dysreflexia (AD)?

Recent Posts